centerforbiosimilars1d
Robert Spina, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Cost-Benefits, Efficacy of Biosimilar Ranibizumab vs Aflibercept for nAMD in Japan
When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...
centerforbiosimilars3d
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...
centerforbiosimilars4d
Gary Fanjiang, MD, MBA, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Dinakaran Balasubramanian
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
Nancy J. Globus, PharmD
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars5d
BioRationality: Biosimilar Associations and Stakeholders Representing Biosimilars
Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as well as how their stakeholder demographic and main objectives differ from ...